<DOC>
	<DOCNO>NCT00547768</DOCNO>
	<brief_summary>Compare effect single dose fexofenadine HCl 180 mg plus orange juice versus placebo plus orange juice change baseline ( pre-dose ) histamine skin flare .</brief_summary>
	<brief_title>Comparative Study Evaluating Effects Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice Skin Wheal Flare Challenge Model .</brief_title>
	<detailed_description />
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>Healthy male nonpregnant , nonlactating female subject ; 1255 year age ; within 15 % normal body weight height body mass index ( BMI ) less 29.9 kg/m2 ; positive histamine skin prick test ( duplicate histamine skin prick test ) summation flare &gt; 20 mm large diluent control , summation wheal &gt; 6 mm large diluent control screen Visit 1 . Asthma require treatment medication inhale , shortacting beta agonist Signs symptom currently active allergic disease ( SAR , perennial allergic rhinitis , episodic allergic rhinitis ) Upper respiratory tract infection , sinusitis , asthma flulike symptom within 2 week prior Visit 1 Dermatographism skin condition might interfere interpretation skin test result Treatment escalate dos immunotherapy , oral immunotherapy , short course ( rush ) immunotherapy Any excessive amount alcohol ( two drinks/day average ) Any excessive use caffeine ( six cup coffee per day equivalent ) Any history chronic alcohol moodaltering drug abuse Any use tobacco/nicotine product within 90 day visit 1 Any disease state surgery know affect gastrointestinal absorption drug Treatment H1receptor antagonist regularly within past year study entry Known hypersensitivity investigational product drug similar chemical property , orange juice Need visit tan salon study Need use artificial tanning product study Pregnancy Breastfeeding Likelihood require treatment study period drug permit clinical study protocol ( see Section 6.2 ) Treatment investigational product last 30 day study entry Clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease make implementation protocol interpretation study result difficult Mental condition render subject unable understand nature , scope , possible consequence study Unlikelihood comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study . Use follow drug within time indicated prior first dose visit ( Time prior Visit 2 ) : Systemic injected corticosteroid ( include oral , parenteral , intravenous , rectal ) ( 30 day ) . Nasal inhale ocular corticosteroid ( 30 day ) . Nasal inhale ipratropium bromide ( atropine ) , inhaled nedocromil , nasal , inhale , ophthalmic sodium cromolyn ( 14 day ) Agents antihistaminic/anticholinergic activity ( e.g.antidepressants , antipsychotic ) ( 14 day ) . Leukotriene pathway modifier ( Accolate® , Singulair® , Zyflo® ) 10 day Ocular antiallergy medication include lodoxamide ( Alomide® ) , olopatadine ( Patanol® ) , emedastine difumarate ( Emadine® ) , levocabastine ( Livostin® ) ( 10 day ) . Nonsteroidal antiinflammatory ophthalmics include ketorolac ( Acular® ) , flurbiprofen ( Ocufen® ) , suprofen ( Profenal® ) , diclofenac ( Voltaren® ) ( 10 day ) . Antihistamines include desloratadine ( Clarinex® ) , loratadine ( Claritin® ) ( 10 day ) . Fexofenadine HCl ( Allegra® ) , cetirizine ( Zyrtec® ) , hydroxyzine , azelastine nasal spray ( Astelin® ) , clemastine ( 7 day ) Other shortacting antihistamine chlorpheniramine drug antihistaminic activity ( 3 day ) . OTC oral antihistamine , decongestant ( include pseudoephedrine decongestant ) , antihistamines/decongestant combination include cold , cough , sleep aid ( 3 day ) . OTC ophthalmic decongestant , antihistamine , decongestant/ antihistamine combination ( 3 day ) . Other anticholinergic agent ( 3 day ) . Immunotherapy injection ( 1 day ) . Other drug permit expect interfere ability subject participate study . Nonsteroidal antiinflammatory agent allow 2 day prior treatment visit day 24 hour postdose . Medications agent specify might confound interpretation result prohibit follow : Caffeine within 6 hour prior visit ( coffee , tea , cola , include Mountain Dew Surge ) . Decaffeinated coffee , tea cola within 6 hour visit Alcohol within 24 hour prior study visit . Chocolate within 6 hour prior visit . Antacids within + 2 hour investigational product dosing . Any waiver inclusion exclusion criterion require approval investigator sponsor casebycase basis prior enrol subject . Approval document sponsor investigator . No subject allow enroll study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>